File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1365-3083.2009.02360.x
- Scopus: eid_2-s2.0-77449128483
- PMID: 20415778
- WOS: WOS:000274805900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders
Title | Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders |
---|---|
Authors | |
Keywords | Chemicals And Cas Registry Numbers |
Issue Date | 2010 |
Publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/SJI |
Citation | Scandinavian Journal Of Immunology, 2010, v. 71 n. 3, p. 125-133 How to Cite? |
Abstract | Public health can be protected most effectively through vaccination programmes. However, while presently available vaccination techniques protects the individual by provoking immune responses against exogenous antigens (ags), such as those associated with certain bacteria and viruses, they cannot protect against or treat mishaps caused by endogenous ag. Recently, Barabas and colleagues have developed a new vaccination method, called modified vaccination technique (MVT), which allows the presentation of disease causing agents in such a way as to initiate and maintain desired immune response outcomes even in the context of mishaps associated with endogenous ag. For example, in an experimental autoimmune kidney disease, the MVT downregulated/terminated pathogenic immune responses that were causing morphological and functional changes of the kidney. The MVT promises, with appropriate case-specific modifications, both preventative and curative applications for ailments, such as endogenous ag initiated mishaps (i.e. autoimmune diseases and cancer) and diseases caused by chronic infection, that are presently only treatable with drugs. To achieve specific immune responses, purified components of the vaccine (ag and antibodies) must be produced and assembled into immune complexes having the potential of inducing predetermined corrective immune response outcomes. © 2010 Blackwell Publishing Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/132544 |
ISSN | 2023 Impact Factor: 4.1 2023 SCImago Journal Rankings: 0.946 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Barabas, AZ | en_HK |
dc.contributor.author | Cole, CD | en_HK |
dc.contributor.author | Barabas, AD | en_HK |
dc.contributor.author | Graeff, RM | en_HK |
dc.contributor.author | Lafreniere, R | en_HK |
dc.contributor.author | Weir, DM | en_HK |
dc.date.accessioned | 2011-03-28T09:26:09Z | - |
dc.date.available | 2011-03-28T09:26:09Z | - |
dc.date.issued | 2010 | en_HK |
dc.identifier.citation | Scandinavian Journal Of Immunology, 2010, v. 71 n. 3, p. 125-133 | en_HK |
dc.identifier.issn | 0300-9475 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/132544 | - |
dc.description.abstract | Public health can be protected most effectively through vaccination programmes. However, while presently available vaccination techniques protects the individual by provoking immune responses against exogenous antigens (ags), such as those associated with certain bacteria and viruses, they cannot protect against or treat mishaps caused by endogenous ag. Recently, Barabas and colleagues have developed a new vaccination method, called modified vaccination technique (MVT), which allows the presentation of disease causing agents in such a way as to initiate and maintain desired immune response outcomes even in the context of mishaps associated with endogenous ag. For example, in an experimental autoimmune kidney disease, the MVT downregulated/terminated pathogenic immune responses that were causing morphological and functional changes of the kidney. The MVT promises, with appropriate case-specific modifications, both preventative and curative applications for ailments, such as endogenous ag initiated mishaps (i.e. autoimmune diseases and cancer) and diseases caused by chronic infection, that are presently only treatable with drugs. To achieve specific immune responses, purified components of the vaccine (ag and antibodies) must be produced and assembled into immune complexes having the potential of inducing predetermined corrective immune response outcomes. © 2010 Blackwell Publishing Ltd. | en_HK |
dc.language | eng | en_US |
dc.publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/SJI | en_HK |
dc.relation.ispartof | Scandinavian Journal of Immunology | en_HK |
dc.subject | Chemicals And Cas Registry Numbers | en_US |
dc.title | Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Graeff, RM: graeffr@hku.hk | en_HK |
dc.identifier.authority | Graeff, RM=rp01464 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1365-3083.2009.02360.x | en_HK |
dc.identifier.pmid | 20415778 | - |
dc.identifier.scopus | eid_2-s2.0-77449128483 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77449128483&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 71 | en_HK |
dc.identifier.issue | 3 | en_HK |
dc.identifier.spage | 125 | en_HK |
dc.identifier.epage | 133 | en_HK |
dc.identifier.eissn | 1365-3083 | - |
dc.identifier.isi | WOS:000274805900001 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Barabas, AZ=7005562572 | en_HK |
dc.identifier.scopusauthorid | Cole, CD=8942475100 | en_HK |
dc.identifier.scopusauthorid | Barabas, AD=7005562583 | en_HK |
dc.identifier.scopusauthorid | Graeff, RM=7003614053 | en_HK |
dc.identifier.scopusauthorid | Lafreniere, R=7006983863 | en_HK |
dc.identifier.scopusauthorid | Weir, DM=7202838101 | en_HK |
dc.identifier.citeulike | 6801041 | - |
dc.identifier.issnl | 0300-9475 | - |